Anti-CD19 chimeric antigen receptor T cell therapy(BiocurePharm)

N/A

Report date: 2024/03/14 18:26:12

Base Information

Drug NameAnti-CD19 chimeric antigen receptor T cell therapy(BiocurePharm)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLeukemia, Lymphoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesN/A

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsLeukemia, Lymphoid

Inactive IndicationsN/A

Other Information

ATC CodeN/A